Racura Oncology Ltd (ASX: RAC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Racura Oncology Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$392.14 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
196.07 million
Earnings per share
-0.062
Dividend per share
N/A
Year To Date Return
-26.01%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Racura Oncology Ltd (ASX: RAC)
Latest News
Share Gainers
Why Chrysos, Endeavour, Racura, and Treasury Wine shares are racing higher today
Share Gainers
Why EOS, Megaport, Racura, and Xero shares are racing higher today
Share Gainers
Why EBR, EOS, Racura, and Woodside shares are rising today
Healthcare Shares
Which ASX biotech's shares have jumped more than 10% on positive clinical trial news?
ASX Share Market News
Why did these ASX shares outperform their peers in 2025?
Share Gainers
Why Brightstar Resources, Immutep, Pilbara Minerals, and Race Oncology shares are roaring higher
Share Fallers
Why Meteoric Resources, Race, Temple & Webster, and West African shares are falling today
Share Gainers
Why Bravura, Dateline, Orthocell, and Race Oncology shares are storming higher
Healthcare Shares
Cancer drug developer's shares race to three-year high, up 20% on new research results
Share Gainers
Why Deterra Royalties, DroneShield, Lindian, and Race Oncology shares are rising today
Healthcare Shares
Guess which ASX All Ords share is up 9% on 'important milestone'
Healthcare Shares
Why did this ASX All Ords healthcare share just rocket 28%?
Frequently Asked Questions
-
No, Racura Oncology does not pay dividends at this time.
-
Sydney-headquartered Racura Oncology listed on the ASX on 13 July 2016.
RAC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Racura Oncology Ltd
Racura Oncology (ASX: RAC) is a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care.
Racura’s lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provide for 20 years of patent protection over RCDS1.
Racura is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications, with Phase 3 clinical programs in acute myeloid leukaemia (AML), Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.
Racura Oncology has collaborated with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle. Racura is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world.
RAC Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 11 Sep 2026 | $2.02 | $0.00 | 0.00% | 68,865 | $2.02 | $2.05 | $1.98 |
| 10 Sep 2026 | $2.02 | $-0.08 | -3.81% | 68,796 | $2.15 | $2.15 | $2.02 |
| 09 Sep 2026 | $2.10 | $-0.03 | -1.41% | 25,353 | $2.15 | $2.15 | $2.05 |
| 08 Sep 2026 | $2.13 | $0.00 | 0.00% | 199,749 | $2.13 | $2.13 | $2.00 |
| 07 Sep 2026 | $2.13 | $0.03 | 1.43% | 46,384 | $2.11 | $2.16 | $2.08 |
| 04 Sep 2026 | $2.10 | $-0.04 | -1.87% | 84,049 | $2.14 | $2.16 | $2.07 |
| 03 Sep 2026 | $2.14 | $-0.07 | -3.17% | 60,366 | $2.21 | $2.21 | $2.12 |
| 02 Sep 2026 | $2.21 | $-0.03 | -1.34% | 59,254 | $2.24 | $2.24 | $2.16 |
| 01 Sep 2026 | $2.24 | $0.11 | 5.16% | 203,739 | $2.19 | $2.30 | $2.14 |
| 31 Aug 2026 | $2.13 | $-0.02 | -0.93% | 60,043 | $2.14 | $2.20 | $2.13 |
| 28 Aug 2026 | $2.15 | $-0.10 | -4.44% | 38,501 | $2.25 | $2.25 | $2.15 |
| 27 Aug 2026 | $2.25 | $0.05 | 2.27% | 140,410 | $2.20 | $2.26 | $2.19 |
| 26 Aug 2026 | $2.20 | $0.08 | 3.77% | 64,119 | $2.12 | $2.20 | $2.12 |
| 25 Aug 2026 | $2.12 | $0.02 | 0.95% | 15,972 | $2.12 | $2.13 | $2.08 |
| 24 Aug 2026 | $2.10 | $0.00 | 0.00% | 49,685 | $2.12 | $2.22 | $2.09 |
| 21 Aug 2026 | $2.10 | $0.00 | 0.00% | 65,569 | $2.10 | $2.16 | $2.03 |
| 20 Aug 2026 | $2.10 | $-0.02 | -0.94% | 51,398 | $2.05 | $2.11 | $2.04 |
| 19 Aug 2026 | $2.12 | $0.00 | 0.00% | 65,032 | $2.12 | $2.12 | $2.00 |
| 18 Aug 2026 | $2.12 | $0.03 | 1.44% | 73,369 | $2.11 | $2.15 | $2.02 |
| 17 Aug 2026 | $2.09 | $0.09 | 4.51% | 110,721 | $2.00 | $2.17 | $2.00 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 05 Jun 2026 | Serge Scrofani | Buy | 11,285 | $30,375 |
On-market trade.
|
| 28 May 2026 | Daniel Tillett | Exercise | 400,000 | $500,000 |
Exercise of options.
|
| 28 May 2026 | Daniel Tillett | Buy | 400,000 | $500,000 |
Exercise of options.
|
| 26 May 2026 | Daniel Tillett | Buy | 400,000 | $500,000 |
Exercise of options.
|
| 26 May 2026 | Daniel Tillett | Exercise | 400,000 | $500,000 |
Exercise of options.
|
| 21 May 2026 | Daniel Tillett | Buy | 248,342 | $310,427 |
Exercise of options.
|
| 21 May 2026 | Daniel Tillett | Exercise | 248,342 | $310,427 |
Exercise of options.
|
| 14 May 2026 | Daniel Tillett | Exercise | 200,000 | $250,000 |
Exercise of options.
|
| 14 May 2026 | Daniel Tillett | Buy | 200,000 | $250,000 |
Exercise of options.
|
| 07 May 2026 | Daniel Tillett | Exercise | 200,000 | $250,000 |
Exercise of options.
|
| 07 May 2026 | Daniel Tillett | Buy | 200,000 | $250,000 |
Exercise of options.
|
| 02 Apr 2026 | Daniel Tillett | Exercise | 200,000 | $250,000 |
Exercise of options.
|
| 02 Apr 2026 | Daniel Tillett | Buy | 200,000 | $250,000 |
Exercise of options.
|
| 19 Feb 2026 | Daniel Tillett | Exercise | 100,000 | $125,000 |
Exercise of options.
|
| 19 Feb 2026 | Daniel Tillett | Buy | 100,000 | $125,000 |
Exercise of options.
|
| 13 Feb 2026 | Daniel Tillett | Sell | 14,000 | $30,100 |
On-market trade.
|
| 11 Feb 2026 | Daniel Tillett | Buy | 62,631 | $150,314 |
On-market trade.
|
| 22 Jan 2026 | Daniel Tillett | Exercise | 400,000 | $500,000 |
Exercise of options.
|
| 22 Jan 2026 | Daniel Tillett | Buy | 400,000 | $500,000 |
Exercise of options.
|
| 18 Dec 2025 | Daniel Tillett | Buy | 12,218 | $31,529 |
On-market trade.
|
| 18 Dec 2025 | Daniel Tillett | Buy | 300,000 | $375,000 |
Exercise of options. 17,760,160 prior Holding
|
| 18 Dec 2025 | Daniel Tillett | Exercise | 300,000 | $375,000 |
Exercise of options.
|
| 26 Nov 2025 | Daniel Tillett | Buy | 22,000 | $58,744 |
On-market trade. As per announcement
|
| 26 Nov 2025 | Peter (Pete) Smith | Buy | 9,433 | $25,027 |
On-market trade.
|
| 25 Nov 2025 | Serge Scrofani | Issued | 23,983 | $69,790 |
Issue of options.
|
| 25 Nov 2025 | Peter (Pete) Smith | Issued | 357,162 | $1,039,341 |
Issue of options.
|
| 25 Nov 2025 | Megan Baldwin | Issued | 45,470 | $132,317 |
Issue of options.
|
| 25 Nov 2025 | Daniel Tillett | Issued | 903,225 | $2,628,384 |
Issue of options. As per announcement on 25-11-2025
|
| 25 Nov 2025 | Daniel Tillett | Exercise | 2,000,000 | $5,820,000 |
Exercise of options. Cashless exercise
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Megan Baldwin | Non-Executive Director | Jan 2025 |
Dr Baldwin has more than 25 years of experience working on therapeutic drug development programs for oncology and ophthalmic indications. Dr Bald win was previously employed at Genentech (now Roche) as a researcher before moving to Genentech's commercial division. Dr Baldwin's experience in oncology drug development includes both preclinical and clinical investigation of inhibitors targeting angiogenic factors involved in tumour growth and spread, as well as management of competitive intelligence activities to support Genentech's early-stage oncology programs. Dr Baldwin currently serves on the boards of Anaxis Pharma, Gertrude Biomedical, and AusBiotech. Dr Baldwin held Directorship with Invex Therapeutics (from 1 February 2021 to 30 June 2024).
|
| Dr Daniel Tillett | Chief Executive OfficerManaging Director | Sep 2019 |
Dr Tillett is the Managing Director and Chief Executive Officer of Racura Oncology. He is a veteran executive in the biotech industry with more than 25 years of management experience and leadership in all aspects of commercial operations including strategy, IP management, sales and marketing, project management, licensing and fundraising. Dr Tillett is the founder and CEO of Nucleics, a private Australian biotechnology company producing and selling DNA sequencing software to the genomics industry. Previously, he was a Senior Lecturer within the School of Pharmacy at La Trobe University.
|
| Dr Peter (Pete) Smith | Executive DirectorExecutive Chairman | Jun 2023 |
Dr Smith has over 35 years of experience in the pharmaceutical and biotech industry, with a focus on therapeutics, oncology. He has been involved in projects at all stages from concept to phase III clinical studies and drug approval. He was previously the CEO of private biotechnology company Myrio Therapeutics and publicly listed Australian companies Alchemia and AMRAD. Prior to moving to Australia, Dr Smith co founded and was Chief Financial Officer of Onyvax Ltd, a cancer immunotherapy company based in London. At the start of his career, he was a Pharmaceuticals Analyst with UBS and HSBC, being involved in transactions including LSE/NASDAQ initial public offerings, fundraisings, and M&A. He is also currently a Director of Amala Therapeutics.
|
| Dr Serge Scrofani | Non-Executive Director | Sep 2024 |
Dr Scrofani has more than 29 years' experience in the healthcare sector, working in global roles across research and strategy, and corporate and business development. After obtaining his PhD Serge undertook postdoctoral research studies at The University of Melbourne and completed a Fulbright postdoctoral fellowship at The Scripps Research Institute, La Jolla California. He served as Vice President of Strategy & Corporate Development at CSL for 13 years where he played a role in multiple strategic initiatives and M&A transactions. Dr Scrofani is currently CEO & Managing Director of private investment firm FinCap Group Holdings Pty Ltd. He is also a Board Member of the Burnet Institute and The Centre for Eye Research.
|
| Mr Peter Webse | Company Secretary | Aug 2016 |
-
|
| Peter Webse | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Dr Daniel Tillett | 20,179,730 | 10.29% |
| Mr Phillip Richard Perry | 7,421,138 | 3.79% |
| Mr Mark Phillip Juan | 6,058,876 | 3.09% |
| Prof Borje Anderson | 3,750,005 | 1.91% |
| The Trust Company (Australia) Limited MOF A/C | 3,420,000 | 1.74% |
| BNP Paribas Nominees Pty Ltd IB AU Noms Retailclient | 2,340,188 | 1.19% |
| Kudoss Investments Pty Ltd Aitken Global Family A/C | 2,314,450 | 1.18% |
| Mr Phillip Richard Perry & Mrs Tetyana Perry Doneska Super Fund A/C | 2,068,500 | 1.06% |
| Mr Sandor Helby | 2,043,000 | 1.04% |
| Mr Kimberley Ross Gartrell & Mrs Jennifer Margaret Gartrell K&J Gartrell Super Fund A/C | 1,755,000 | 0.90% |
| Mr Alan Giles Sauran | 1,333,888 | 0.68% |
| Ms Marinella Messina | 1,302,661 | 0.66% |
| Mr Anthony James Robinson The Peeko Family No 86 A/C | 1,279,055 | 0.65% |
| Surpion Pty Ltd M W Suhr & Co A/C | 1,250,000 | 0.64% |
| Mr Brian James Walker | 1,168,110 | 0.60% |
| Citicorp Nominees Pty Limited | 1,161,845 | 0.59% |
| Mr Mark Phillip Juan i | 1,149,164 | 0.59% |
| Mr Beau Thomas Robinson Beau Robinson Invstmnt A/C | 966,760 | 0.49% |
| 3rd Man Risk Consulting Pty Limited | 815,000 | 0.42% |
| Mr Ross Earl Henry | 800,000 | 0.41% |
